Eli Lilly & Co. vs. Prelude Therapeutics Incorporated
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | PRLD | |
|---|---|---|
| Market Cap | $1.05 trillion | $442.91 million |
| Revenue (TTM) | $79.67 billion | $22.42 million |
| Net Income (TTM) | $26.71 billion | $-60,488,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | PRLD | |
|---|---|---|
| P/E Ratio | 39.62 | — |
| Price / Book | 31.05 | 3.31 |
| Price / Sales | 13.20 | 19.75 |
LLY and PRLD split the valuation factors evenly.
Profitability
| LLY | PRLD | |
|---|---|---|
| Net Margin | 33.53% | -269.75% |
| Return on Equity | 78.84% | -45.23% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | PRLD | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and PRLD split the dividend factors evenly.
Risk & Sentiment
| LLY | PRLD | |
|---|---|---|
| Short Interest | 1.29% | 0.01% |
PRLD leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, PRLD overview, PRLD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.